Sanofi’s Venglustat Priority Review Is a Rare Disease Pricing License, Not Just a Clinical Win
FDA's 6-month priority review clock for Sanofi's venglustat in type 3 Gaucher disease—affecting fewer than 1,000 Americans—sets up one...
AstraZeneca’s Baxfendy Approval Isn’t a Hypertension Win — It’s a $40 Billion Market Wedge
FDA approved AstraZeneca's baxdrostat (Baxfendy) on May 18, 2026 — the first aldosterone synthase inhibitor for hypertension. Here's what...
Novo Nordisk’s 20.7% Weight Loss Number Changes the GLP-1 Rulebook
Novo Nordisk's Wegovy 7.2 mg CHMP approval delivers 20.7% mean weight loss — rewriting competitive benchmarks for Eli Lilly's...
Roche’s Giredestrant ASCO Play Is a Signal to Every Endocrine Therapy Competitor
Roche's giredestrant lidERA data at ASCO 2026 targets early breast cancer across menopause status — and the $4.3B aromatase...
Novo Nordisk’s Weekly Insulin Isn’t Just a Dosing Upgrade — It’s a Strategic Lifeline in a GLP-1 World
FDA approval of once-weekly insulin icodec-abae (Awiqli) gives Novo Nordisk a differentiated basal insulin, but peak sales of $1.2B...
Lilly’s $300M CrossBridge Bet Isn’t About ADCs — It’s About Buying the Next Decade of Oncology Pricing Power
Eli Lilly's $300M acquisition of CrossBridge Bio targets dual-payload ADCs — a manufacturing cost doubler that signals a bold...
Lilly’s Oral Pivot: Foundayo’s Maintenance Data Isn’t a Scientific Win — It’s a Market Access Weapon
Lilly's ATTAIN-MAINTAIN trial shows Foundayo maintains weight loss after injectable GLP-1s — a $42B market's access problem just found...
Ovarian Cancer’s PARP Inhibitor Gold Rush Is Over — What Comes Next Will Separate the Winners From the Wreckage
PARP inhibitors reshaped ovarian cancer treatment, but with olaparib holding 38% market share and biomarker limits exposed, the next...
AstraZeneca’s Tozorakimab Has Already Won the COPD Biologic Race — The Market Just Doesn’t Know It Yet
AstraZeneca's tozorakimab hit dual Phase III endpoints in COPD via OBERON and TITANIA, targeting a $1.68B biologic market with...
IBTROZI’s 89.8% Response Rate Is a Launch Story — The Real Prize Is What Comes After First-Line
Nuvation Bio's IBTROZI hit $18.5M in Q1 2026 revenue with 600+ patients on drug. The first-line TKI-naïve data makes...